Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 5 November 2009, doi:10.1136/bmj.b4360
Cite this as: BMJ 2009;339:b4360
The risk is uncertain, so patients should make an informed decision
| The first 150 words of the full text of this article appear below. |
Success in giving up smoking can be improved through social support, problem solving or skills training, and various drugs. A combination of drugs and other treatments is most effective.1 Drugs include nicotine replacement products, varenicline (Champix), and bupropion (Zyban and generics). Varenicline and bupropion inhibit the craving to smoke through unknown mechanisms. Both drugs influence the dopamine system, which regulates cognition, mood, and behaviour.2 Both varenicline and bupropion have been associated with "changes in behaviour, agitation, depressed mood, suicidal ideation, and attempted and completed suicide" in patients who had no psychiatric history and were not taking psychotropics.3 4 Nicotine replacement products have no such known associations.3 In the linked study (doi:10.1136/bmj.b3805), Gunnell and colleagues report the first retrospective cohort study to examine suicidal thoughts and behaviours after exposure to smoking cessation products.5
In the United States, changes to labelling of varenicline have been based on biological plausibility and voluntary
Jill E Lavigne, associate professor1,2
1 Wegmans School of Pharmacy, St John Fisher College, Rochester, New York, NY 14618, USA, 2 Department of Veterans Affairs, Canandaigua VA Medical Center, Veterans Integrated Service Network 2, Center of Excellence, Canandaigua, New York, USA
jlavigne@sjfc.edu